240 related articles for article (PubMed ID: 21484485)
1. Does impaired gallbladder function contribute to the development of Barrett's esophagus and esophageal adenocarcinoma?
Nassr AO; Gilani SN; Atie M; Abdelhafiz T; Connolly V; Hickey N; Walsh TN
J Gastrointest Surg; 2011 Jun; 15(6):908-14. PubMed ID: 21484485
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
3. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.
Stein HJ; Kauer WK; Feussner H; Siewert JR
J Gastrointest Surg; 1998; 2(4):333-41. PubMed ID: 9841990
[TBL] [Abstract][Full Text] [Related]
4. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
5. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
6. Management of Barrett's esophagus free of dysplasia.
DeMeester SR
Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):279-84. PubMed ID: 9263346
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
8. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
9. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.
Sarr MG; Hamilton SR; Marrone GC; Cameron JL
Am J Surg; 1985 Jan; 149(1):187-93. PubMed ID: 3966636
[TBL] [Abstract][Full Text] [Related]
10. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the development of Barrett's epithelium in the esophageal remnant postesophagectomy.
O'Riordan JM; Tucker ON; Byrne PJ; McDonald GS; Ravi N; Keeling PW; Reynolds JV
Am J Gastroenterol; 2004 Feb; 99(2):205-11. PubMed ID: 15046206
[TBL] [Abstract][Full Text] [Related]
12. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens.
Sato T; Miwa K; Sahara H; Segawa M; Hattori T
Anticancer Res; 2002; 22(1A):39-44. PubMed ID: 12017320
[TBL] [Abstract][Full Text] [Related]
13. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
[TBL] [Abstract][Full Text] [Related]
14. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
15. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
16. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma.
Katzka DA; Reynolds JC; Saul SH; Plotkin A; Lang CA; Ouyang A; Jimenez S; Cohen S
Am J Med; 1987 Jan; 82(1):46-52. PubMed ID: 3799692
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
[TBL] [Abstract][Full Text] [Related]
18. Role of retinoid X receptor mRNA expression in Barrett's esophagus.
Brabender J; Lord RV; Metzger R; Park J; Salonga D; Danenberg KD; Hölscher AH; Danenberg PV; Schneider PM
J Gastrointest Surg; 2004; 8(4):413-22. PubMed ID: 15120365
[TBL] [Abstract][Full Text] [Related]
19. [Barrett's esophagus, gastroesophageal acid reflux and duodenogastric reflux during the digestive and postprandial period].
Li V; Bost R; Caravel JP; Fournet J; Hostein J
Gastroenterol Clin Biol; 1992; 16(12):978-83. PubMed ID: 1493899
[TBL] [Abstract][Full Text] [Related]
20. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
